Recruiting patients who have fatty liver diagnosed by their doctor, usually related to obesity and diabetes to try and improve fibrosis (cirrhosis) of their liver in a doubled blinded placebo-controlled trial. Patient cannot have alcohol related liver disease or far advanced cirrhosis.

Patients must have a confirmed diagnosis of NASH and a fibrosis score of 4 based on NASH CRN scoring system determined by central reading of liver biopsy obtained no more than 12 months before beginning study ages greater than 18 years old.